A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC) Locally Advanced or Metastatic with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)

Brief description of study

If you have been diagnosed with Non-Small Cell Lung Cancer that has tested positive for the presence of EGFR or HER2 Exon 20 Insertion (lung cancer that involves a certain type of mutated or changed cells that may play a role in causing your cancer to grow and spread), you may qualify for this phase 2 study. The main goal of this research study is to determine the safety and how effective the investigational drug, Poziotnib, a targeted therapy designed to slow or stop certain types cancer cells by targeting specific changed or mutated molecules that help cancer cells grow or spread, is for the treatment for EGFR or HER2 Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer (NSCLC).


Clinical Study Identifier: s17-01530
ClinicalTrials.gov Identifier: NCT03318939
Principal Investigator: Elaine Shum
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.